Aequus raises Over $5 Million Through Public Offering

Aequus Pharmaceuticals (TSX VENTURE:AQS) (OTCQB:AQSZF) raised $5,175,000 million through a public offering.
As quoted in the press release:

Pursuant to the Offering, the Company issued 17,250,000 units (the “Units”) at a price of $0.30 per Unit, for aggregate gross proceeds to Aequus of $5,175,000. Canaccord Genuity Corp. (the “Underwriter”) acted as underwriter for the Offering. The 17,250,000 Units issued include 2,250,000 Units issued and sold pursuant to the over-allotment option granted by the Company to the Underwriter, which was exercised in full.
Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one Common Share (a “Warrant Share”) for a period of two years at an exercise price of $0.45 per Warrant Share, subject to adjustment in certain events. In the event that the volume weighted average trading price of the Company’s Common Shares on the TSX Venture Exchange is greater than $0.80 per Common Share for a period of 15 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof by way of press release and in such case the Warrants will expire on the 30th day after such notice is given.
In addition, Aequus issued to the Underwriter a total of 862,500 broker warrants (the “Broker Warrants”) in connection with the Offering. Each such Broker Warrant entitles the holder to acquire a Unit at an exercise price of $0.30 per Unit for a period of two years following the closing of the Offering.
Net proceeds of the Offering are to be used for the development of the Company’s drug pipeline and other general corporate purposes.
The Units were offered by way of a prospectus supplement and an accompanying short form base shelf prospectus of the Company, in the provinces of Alberta, British Columbia, Saskatchewan, Manitoba and Ontario, and in the United States by way of private placement to qualified institutional investors.
The Units issued pursuant to the Offering have not been, nor will they be, registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX VENTURE:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

Click here to read the full press release.